Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer
Dickhoff, C, Dahele, M, Paul, M.A, van de Ven, P.M, de Langen, A.J, Senan, S, Smit, E.F, Hartemink, K.J
Published in Lung cancer (Amsterdam, Netherlands) (01.04.2016)
Published in Lung cancer (Amsterdam, Netherlands) (01.04.2016)
Get full text
Journal Article
The force of HER2 – A druggable target in NSCLC?
Jebbink, M., de Langen, A.J., Boelens, M.C., Monkhorst, K., Smit, E.F.
Published in Cancer treatment reviews (01.06.2020)
Published in Cancer treatment reviews (01.06.2020)
Get full text
Journal Article
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer
van der Wekken, A J, Pelgrim, R, 't Hart, N, Werner, N, Mastik, M F, Hendriks, L, van der Heijden, E H F M, Looijen-Salamon, M, de Langen, A J, Staal-van den Brekel, J, Riemersma, S, van den Borne, B E, Speel, E J M, Dingemans, A-M C, Hiltermann, T J N, van den Berg, A, Timens, W, Schuuring, E, Groen, H J M
Published in Clinical cancer research (01.08.2017)
Published in Clinical cancer research (01.08.2017)
Get full text
Journal Article
The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer
Joosten, P.J.M., de Langen, A.J., van der Noort, V., Monkhorst, K., Klomp, H.M., Veenhof, A.A.F.A., Dickhoff, C., Smit, E.F., Hartemink, K.J.
Published in Lung cancer (Amsterdam, Netherlands) (01.11.2021)
Published in Lung cancer (Amsterdam, Netherlands) (01.11.2021)
Get full text
Journal Article
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC
Jebbink, M., de Langen, A.J., Monkhorst, K., Boelens, M.C., van den Broek, D., van der Noort, V., de Gooijer, C.J., Mahn, M., van der Wekken, A.J., Hendriks, L., Hashemi, S.M.S., Paats, M.S., Dingemans, A.C., Smit, E.F.
Published in JTO clinical and research reports (01.04.2023)
Published in JTO clinical and research reports (01.04.2023)
Get full text
Journal Article
The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling
Zwierenga, F., Zhang, L., Melcr, J., Schuuring, E., van Veggel, B.A.M.H., de Langen, A.J., Groen, H.J.M., Groves, M.R., van der Wekken, A.J.
Published in Lung cancer (Amsterdam, Netherlands) (01.09.2024)
Published in Lung cancer (Amsterdam, Netherlands) (01.09.2024)
Get full text
Journal Article
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
van Veggel, B., Madeira R Santos, J.F. Vilacha, Hashemi, S.M.S., Paats, M.S., Monkhorst, K., Heideman, D.A.M., Groves, M., Radonic, T., Smit, E.F., Schuuring, E., van der Wekken, A.J., de Langen, A.J.
Published in Lung cancer (Amsterdam, Netherlands) (01.03.2020)
Published in Lung cancer (Amsterdam, Netherlands) (01.03.2020)
Get full text
Journal Article
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort
van der Wel, J.W.T., Jebbink, M., van den Broek, D., Steinbusch, L.C., Theelen, W.S.M.E., Ruiter, G., Buikhuisen, W., Burgers, J.A., Baas, P., Vermeulen, M., van der Noort, V., Hashemi, S.M.S., Bosch, L.J.W., Monkhorst, K., Smit, E.F., Boelens, M.C., de Langen, A.J.
Published in Lung cancer (Amsterdam, Netherlands) (01.09.2024)
Published in Lung cancer (Amsterdam, Netherlands) (01.09.2024)
Get full text
Journal Article
1305P Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
Skoulidis, F., Li, B.T., Hochmair, M.J., Govindan, R., Vincent, M., Van Der Wekken, A.J., Reguart Aransay, N., O'Byrne, K.J., Girard, N., Griesinger, F., Nishio, M., Häfliger, S., Lindsay, C., Reinmuth, N., Paulus, A., Papakotoulas, P., Obiozor, C., Nduka, C., Wang, Y., De Langen, A.J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1262P Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance
van der Wel, T., Jebbink, M., Badrising, S., Steinbusch, L., Ruiter, G., Theelen, W.S.M.E., Veggel, B.V., Smit, J., Hashemi, S., Van Der Wekken, A.J., Hendriks, L.E., Paats, M.S., Ernst, S., Van Den Broek, D., Bosch, L.J.W., Monkhorst, K., Smit, E.F., Boelens, M.C., De Langen, A.J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
P2.10-07 ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases
van der Wel, T., Boelens, M.C., Jebbink, M., Smulders, S.A., Tiemessen, M.A., Maas, K.W., Luitse, M.J., Compter, A., Boltjes, R.P.B., Sol, N., Monkhorst, K., van den Broek, D., Smit, E.F., de Langen, A.J., Brandsma, D.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1
Sherif, B., Besse, B., Solomon, B., Bazhenova, L., Kim, D.W., Lin, J.J., Wolf, J., Popat, S., Goto, K., de Langen, A.J., Springfeld, C., Reynolds, M., Odom, D., Yuan, Y., Lee, A., Blum, S.I., Thamake, S., Ades, F., Drilon, A.
Published in Value in health (01.12.2023)
Published in Value in health (01.12.2023)
Get full text
Journal Article
1214P High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20
Zwierenga, F., van Veggel, B.A.M.H., Hendriks, L.E.L., Hiltermann, T.J.N., Hiddinga, B.I., Hijmering-Kappelle, L.B.M., Dingemans, A-M.C., van der Leest, C., de Langen, A.J., van den Heuvel, M., van der Wekken, A.J.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
Yu, H.A., Ambrose, H., Baik, C., Cho, B.C., Cocco, E., Goldberg, S.B., Goldman, J.W., Kraljevic, S., de Langen, A.J., Okamoto, I., Piotrowska, Z., Pluta, M., Powar, S., Aransay, N. Reguart, Riess, J.W., Le, X.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
1740P Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to second-line osimertinib treatment in patients with EGFR mutation positive (EGFRm) NSCLC
Jebbink, M., van der Wel, J.W.T., van den Broek, D., Boelens, M.C., Monkhorst, K., Ruiter, G., Burgers, S., Steinbusch, L., Baas, P., Kastelijn, L., van der Wall, E.E., Stellingwerf, M., Smit, E.F.F., de Langen, A.J.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
EP08.02-019 Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Spira, A., Spigel, D.R., Camidge, R., de Langen, A.J., Kim, T.M., Goto, K., Elamin, Y., Shum, E., Reckamp, K.L., Rotow, J., Goldberg, S., Gadgeel, S., Leal, T.A., Albayya, F., Fitzpatrick, S., Louie-Gao, M., Parepally, J., Zalutskaya, A., Yu, H.
Published in Journal of thoracic oncology (01.09.2022)
Published in Journal of thoracic oncology (01.09.2022)
Get full text
Journal Article
MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02
Janne, P., Goto, Y., Kubo, T., Ninomiya, K., Kim, S.-W., Planchard, D., Ahn, M.-J., Smit, E.F., de Langen, A.J., Pérol, M., Pons-Tostivint, E., Novello, S., Hayashi, H., Shimizu, J., Kim, D.-W., Pereira, K., Cheng, F.-C., Taguchi, A., Cheng, Y., Goto, K.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial
Cho, B.C., Camidge, D.R., Lin, J.J., Kim, S.-W., Solomon, B., Dziadziuszko, R., Besse, B., Goto, K., de Langen, A.J., Wolf, J., Lee, K.H., Popat, S., Springfeld, C., Nagasaka, M., Felip, E., Yang, N., Lu, S., Kao, S., Velcheti, V., Cheema, P., Stopatschinskaja, S., Mehta, M., Trone, D., Ades, F., Calvet, C.Y., Drilon, A.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study
Johnson, M.L., de Langen, A.J., Waterhouse, D.M., Mazieres, J., Dingemans, A-M.C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Okamoto, I., Kim, S-W., Linardou, H., Novello, S., Chen, Y., Solomon, B., Obiozor, C., Wang, Y., Paz-Ares, L.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article